The nucleolus directly regulates p53 export and degradation by Boyd, Mark T. et al.
JCB: Article
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 194 No. 5  689–703
www.jcb.org/cgi/doi/10.1083/jcb.201105143 JCB 689
M.T. Boyd and N. Vlatković contributed equally to this paper.
Correspondence to Carlos P. Rubbi: c.rubbi@liv.ac.uk
Abbreviations used in this paper: BME, -mercaptoethanol; CHX, cycloheximide; 
DIC, differential interference contrast; FLIP, fluorescence loss in photobleaching; 
LMB, leptomycin B; NES, nuclear export signal; PI, protease inhibitor; ROI, re-
gion of interest; SIE, stress-independent export; SLIP, standard lysis and immuno-
precipitation; SSE, stress-sensitive export.
Introduction
The levels of the p53 tumor suppressor protein are regulated 
posttranscriptionally, with MDM2-mediated ubiquitylation and   
proteasomal degradation playing a major role (Ljungman, 2000;   
Marine and Lozano, 2010). p53 stabilization ensues by abro-
gation of this degradation, but the wide variety of cell stresses 
that can cause it has led to the proposal of a large number of 
activator proteins and pathways, all converging on the disrup-
tion of the p53–MDM2 interaction. In a radically different view 
of stress-induced p53 stabilization, we have proposed that func-
tional nucleoli are required for MDM2 to promote p53 degrada-
tion (Rubbi and Milner, 2003). Because nucleolar function is 
extremely sensitive to cellular stresses, it can act as a unify-
ing stress sensor signaling to p53: its impairment determines 
that p53 can no longer be degraded, and a p53 response ensues 
by default (Rubbi and Milner, 2003; Horn and Vousden, 2004; 
Olson, 2004; Mayer and Grummt, 2005). However, contem-
porary with our model, several transducers of nucleolar stress 
into p53 stabilization have been proposed, such as ribosomal   
L proteins, B23 (also called nucleophosmin), PML, etc., which 
are suggested to act mainly via the extensive relocalization of 
components caused by nucleolar disruption followed by their 
interaction with either p53 or MDM2 (Colombo et al., 2002; 
Lohrum et al., 2003; Zhang et al., 2003; Bernardi et al., 2004; 
Bhat et al., 2004; Dai and Lu, 2004; Dai et al., 2004; Jin et al., 
2004; Kurki et al., 2004). Hence, although the link between 
nucleolar/ribosomal stress and p53 stabilization is widely ac-
knowledged, we now have two views for the underlying mecha-
nism: one based on relocalization of diffusible components that 
can disrupt the p53–MDM2 interaction; the other based on a 
direct involvement of the nucleolus in p53 ubiquitylation and 
transport. This work aims to resolve these views by determining 
whether the nucleolus has a direct role in p53 regulation.
In addition, there is a more fundamental reason to study the 
nucleolar dependence of p53 regulation, which stems from the fact   
that nucleolar localization is conspicuous in both p53 and MDM2 
biochemistry. Klibanov et al. (2001) have shown that p53 accumu-
lates in a nucleolus-bound form after proteasomal inhibition. MDM2, 
on the other hand, has been proposed to transit through nucleoli and   
to be retained in nucleoli after actinomycin D treatment (Mekhail   
et al., 2005), as opposed to many nucleolar proteins whose   
T
he  correlation  between  stress-induced  nucleolar 
disruption  and  abrogation  of  p53  degradation 
is evident after a wide variety of cellular stresses. 
This  link  may  be  caused  by  steps  in  p53  regulation   
occurring in nucleoli, as suggested by some biochemical 
evidence. Alternatively, nucleolar disruption also causes 
redistribution of nucleolar proteins, potentially altering 
their interactions with p53 and/or MDM2. This raises the 
fundamental question of whether the nucleolus controls 
p53 directly, i.e., as a site where p53 regulatory pro-
cesses occur, or indirectly, i.e., by determining the cellular 
localization  of  p53/MDM2-interacting  factors.  In  this 
work,  transport  experiments  based  on  heterokaryons, 
photobleaching,  and  micronucleation  demonstrate  that 
p53 regulatory events are directly regulated by nucleoli 
and are dependent on intact nucleolar structure and func-
tion. Subcellular fractionation and nucleolar isolation re-
vealed a distribution of ubiquitylated p53 that supports 
these findings. In addition, our results indicate that p53 is 
exported by two pathways: one stress sensitive and one 
stress insensitive, the latter being regulated by activities 
present in the nucleolus.
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p53 (Lohrum et al., 2000). In addition, nucleolar sequestration   
of MDM2 by CDKN2A (p14ARF) is a well-documented p53 
stabilization pathway (Sherr and Weber, 2000). Hence, nucleolar 
localization and trafficking are recurrent observations in p53 and 
mobility increases after ribosomal stress (Chen and Huang, 2001). 
Also, MDM2 appears to be exported to the cytoplasm via the   
nucleolus (Tao and Levine, 1999b). It is also possible that MDM2   
may require its nucleolar localization signal to polyubiquitylate   
Figure 1.  p53 steady-state levels in hetero-
karyons. (A) Example of staining and identifi-
cation of heterokaryons produced by fusion of 
U2Os (H, human) and 3T3 (M, murine) cells. 
Labeling: anti–murine p53 (PAb246). (B–E) Fu-
sion of U2Os and 3T3 cells in normal growth 
and UV irradiation (20 J/m
2). Cells were ei-
ther left untreated (B and C) or UV irradiated 
(U2Os in D; 3T3 in E). Cells were fused 5 h 
after irradiation and cultured for a further 6 h 
(in D and E with 50 µg/ml CHX). Labeling anti-
bodies  are  indicated.  Cocytoplasmic  nuclei 
are included within a perimeter.691 Nucleolar regulation of p53 • Boyd et al.
or degradation can be transmitted from one nucleus to another 
(i.e., whether or not it is diffusible). If two nuclei reside within 
a common cytoplasm (cocytoplasmic in a heterokaryon), would 
a stressed nucleus increase the p53 half-life in a nonstressed   
nucleus, or would the latter reduce the p53 half-life in the stressed 
one? This experiment has three possible outcomes: p53 stabili-
zation in both nuclei, p53 degradation in both, or p53 stabiliza-
tion only in the stressed nucleus. The first two (nonlocal control) 
would indicate that the mediators of p53 stability are free to 
move within and between nuclei, whereas the third (local con-
trol) would indicate that p53 stability is determined by a non-
translocating (nucleus bound) component.
We  generated  heterokaryons  (Fig.  1  A)  between  cells 
with different p53 half-lives (human U2Os and murine NIH3T3 
[3T3] with t1/2 = 29.5 ± 4.6 and 13.7 ± 4.2 min, respectively; 
Fig. S1 A). Both human and murine p53, when examined in 
their homologous nuclei, showed no difference between nuclei 
inside a heterokaryon (fused) and nuclei outside a heterokaryon 
(nonfused; Fig. 1, B and C; and summarized in Table I). Thus, 
the presence of a human nucleus did not alter the murine p53 
steady-state levels in a murine nucleus or vice versa. However, 
both human and murine p53 showed higher levels in human 
(U2Os) nuclei than in murine (3T3) nuclei (Fig. 1, B and C; 
Table I; and Fig. S1 B), correlating with the differences in p53 
half-life in the individual cell lines. Cells had been fused for 
6 h before fixation, so over that time, they shared the newly 
synthesized transcriptome and proteome (no protein synthesis 
inhibitor added). Thus, the p53 steady-state level in a nucleus 
is a property intrinsic to it (i.e., is locally controlled) and is not 
affected by the proteome contributed by a heterologous cocyto-
plasmic nucleus.
p53 stabilization is a local property of a 
stressed nucleus
Because the experiment in Fig. 1 showed that p53 levels were 
a property intrinsic to each nucleus, we next examined whether 
this continued to be true in nuclei that had been subjected   
to genotoxic stress induced by UV irradiation. To analyze 
MDM2 biology that can be expected to be of biological signifi-
cance. Yet, surprisingly, to date, we do not have a model of p53 
regulation that manages to account for these nucleolar localization 
and transport features. This work therefore addresses the funda-
mental question of whether nucleoli constitute a cellular compart-
ment in which key steps in p53 regulation occur.
First, work was focused on determining whether the main 
p53 regulator was a stable nuclear structure (here hypothesized to 
be the nucleolus) or diffusible mediators. Heterokaryon (cell fusion) 
assays showed that the p53 level in each nucleus is a property intrin-
sic to the nucleus and that p53 stabilization is only local to a stressed 
nucleus. Furthermore, the presence of a nonstressed nucleus in a 
heterokaryon did not reduce the levels of p53 in a cocytoplasmic 
stressed nucleus, nor did a stressed nucleus raise p53 steady-state 
levels in a cocytoplasmic nonstressed nucleus. Next, micronuclea-
tion revealed that within a single cell, micronuclei without nucleoli 
have higher steady-state levels of p53, directly confirming the role 
of nucleoli. Furthermore, if the nucleolus directly regulates p53, 
p53 must transit through the nucleolus, such that all p53 molecules 
(or at least the vast majority) are nucleolar at some point. Such 
transit is demonstrated here by fluorescence loss in photobleaching 
(FLIP; Lippincott-Schwartz et al., 2003) using a cell line stably ex-
pressing p53-EGFP. Results show that clearance of the p53-EGFP 
fluorescence  is  comparably  fast  by  nucleoplasmic  or  nucleolar 
photobleaching. In addition, subcellular fractionation experiments 
demonstrate that nucleolar p53 is ubiquitylated, with a distinctive 
pattern showing more polyubiquitylation than in the nucleoplasm 
and cytoplasm. Finally, our transport experiments reveal that there 
are two pathways of p53 nuclear export: one stress sensitive and 
one insensitive, the latter being regulated by the nucleolus.
Results
p53 steady-state level is a property local 
to a nucleus
We reasoned that the key to deciding which model best ex-
plained the nucleolar control of p53 levels was to address the 
fundamental question of whether signaling for p53 stabilization 
Table I.  Analysis of mean nuclear p53 immunofluorescence intensities in human/mouse heterokaryons
Irradiated cells Treatment p53 detected Nuclei compared p53 signal ratio P-value
None Untreated Human H inside/H outside 1.20 0.4567
H inside/M inside 4.30 1.5 × 10
8
None Untreated Murine M inside/M outside 2.83
a 0.1962
H inside/M inside 4.77 6.4 × 10
7
Murine Untreated Human H inside/M inside 1.06 0.5735
Human CHX Human H outside/H inside 2.16 0.0172
Human MG132 + CHX Human H outside/H inside 1.34 0.0266
H inside/M inside 1.02 0.9985
Human LMB + CHX Human H outside/H inside 1.17 0.1491
H inside/M inside 11.4 3.0 × 10
3
Human or murine p53 was detected with the species-specific mAbs DO-1 or PAb246, respectively. Inside and outside indicate being part or not of a heterokaryon, 
respectively, i.e., fused with a heterologous nucleus or not. p53 signal ratio indicates the average ratio of p53 mean intensities in each of the two types of nuclei 
compared. This value is only illustrative because the paired t test was used to establish the statistical difference between p53 mean intensities. P-value indicates the   
t test for the differences between the p53 nuclear fluorescence intensities under various conditions. Neighboring nuclei (both within and outside heterokaryons) from 
each field of view were compared. A paired t test was then applied to collate data from several fields. H, human; M, murine.
aThis quantitation is unreliable because it corresponds to basal levels of murine p53 in 3T3 fibroblasts. Nevertheless, the p-value indicates that the presence of a 
nonstressed human nucleus in a heterokaryon does not significantly alter the p53 levels in the murine nucleus.JCB • VOLUME 194 • NUMBER 5 • 2011   692
Distinct pathways determine p53 
nucleocytoplasmic translocation
Irradiated nuclei show a reduction in p53 levels when they are 
fused with nonirradiated ones compared with nonfused irradi-
ated nuclei (Fig. 1, D and E; Table I; and Fig. S1, C and D, 
images and plots). Thus, some p53 is stabilized by irradiation 
(i.e., persistent for 6 h in CHX), but some appears to be de-
gradable if a nonstressed nucleus is present. This degradable 
fraction of p53 does in fact reach the nonstressed nucleus, as 
indicated by the even distribution of p53 in all nuclei within a 
heterokaryon when proteasome degradation is inhibited with 
MG132 (Fig. 2 A and Table I). Notice that when cells are treated 
with MG132, p53 levels (detected with an antibody specific for 
human p53) are slightly but significantly lower in U2Os nuclei 
in heterokaryons than in the nuclei of nonfused cells (Fig. 2 A  
and Table I), likely reflecting a dilution effect caused by trans-
port  to  the  fused  nucleus.  The  translocation  of  p53  and  its 
reaching a nonstressed nucleus (indicated by detection under 
conditions of proteasome inhibition) appear to be necessary for 
degradation because nuclear export inhibition by leptomycin   
B (LMB; Fornerod et al., 1997) preserves p53 stabilized levels 
in the irradiated nucleus (Fig. 2 B and Table I). It should be 
noted, however, that although p53 levels determined by immuno-
fluorescence do not appear to show a statistical difference be-
tween LMB-treated U2Os fused and nonfused nuclei (Table I),   
it is possible that a small fraction of p53 (not resolved by immuno-
fluorescence quantitation) may still be able to exit the U2Os 
nucleus under LMB treatment (see discussion of Fig. 3). In 
conclusion, a fraction of p53 that cannot be degraded by an ir-
radiated nucleus can still be exported to the cytoplasm, and if it 
reaches a nonstressed nucleus, it can still be degraded.
Because the level of p53 in a human irradiated nucleus in 
a heterokaryon does not increase in the presence of MG132 but 
the level in a cocytoplasmic (i.e., fused) murine nucleus does 
(Fig. 1 D and Fig. 2 A), it follows that a fraction of p53 is ex-
ported from a stressed nucleus and can be degraded in a location 
not exposed to the stress. Two modes of p53 nuclear export 
are therefore evident: one in which the export of a proportion 
of nuclear p53 is inhibited by cellular stress leading to nuclear 
local versus nonlocal p53 stabilization under cell stress, het-
erokaryons were prepared with the seeded cell line UV irradi-
ated and incubated for 5 h before fusion. After fusion with 
nonstressed cells, heterokaryons were incubated for a further   
6 h with cycloheximide (CHX) to inhibit de novo p53 synthesis 
to reveal any p53 degradation that might occur. As shown in   
Fig. 1 (D and E), in the presence of CHX in heterokaryons, 
p53  is  only  detectable  in  irradiated  nuclei  irrespective  of 
whether these are from 3T3 or U2Os cells, with nonirradiated 
nuclei showing levels similar to the extranuclear background. 
Fig. S1 (C and D) shows a gallery of images and quantitation 
for the experiments shown in Fig. 1 (D and E), confirming that 
fusion of murine or human irradiated nuclei with heterologous 
nonirradiated nuclei leads to a reduction in p53 levels (com-
pare with nonfused irradiated nuclei). Thus, p53 stabilization 
is local to a stressed nucleus. This simple yet novel observa-
tion puts a constraint on any model of p53 regulation: it must 
be able to explain the asymmetric p53 stabilization between 
cocytoplasmic  stressed  and  nonstressed  nuclei  (notice  that 
in the presence of de novo synthesis p53 levels in stressed 
3T3 nuclei are only slightly higher than in nonstressed U2Os   
nuclei, and thus, subsequent experiments used U2Os as the 
target for stress; Fig. S1 B).
The  intranuclear  and  nucleocytoplasmic  movement   
of components proposed to mediate stress signaling to p53 
has been extensively documented both in normal and stressed 
conditions (see further confirmation regarding the transloca-
tion of factors previously suggested to be determinants of p53 
stability in Fig. S1, E–H; Borer et al., 1989; Finch and Chan, 
1996; Tao and Levine, 1999a,b; Chen and Huang, 2001; Leary 
et al., 2004; Tsai and McKay, 2005; Lam et al., 2007). Thus,   
local p53 stabilization is difficult to explain by models based 
on p53- or MDM2-interacting proteins being redistributed 
by  nucleolar  stress  (the  case  of  ribosomal  protein  L11  is 
analyzed in Fig. S1, K–N), and therefore, based upon our 
previous work demonstrating the central role of nucleolar 
stress in p53 stabilization, a model in which p53 regulation 
occurs in a functional nucleolus appears to be a better fit to 
the observations.
Figure  2.  p53  transport  in  heterokaryons.  
(A) UV-irradiated U2Os fused to 3T3 cells as in 
Fig. 1 D with the addition of 10 µM MG132 and   
50  µg/ml  CHX  after  fusion.  (B)  UV-irradiated 
U2Os fused to 3T3 cells as in Fig. 1 D with 
the  addition  of  20  nM  LMB  and  50  µg/ml 
CHX after fusion. In both cases, labeling was 
for human p53 (DO-1). H, human U2O cells; 
M, murine 3T3 cells. Cocytoplasmic nuclei are 
included within a perimeter.693 Nucleolar regulation of p53 • Boyd et al.
which appears to behave similarly to endogenous p53 because 
it can be stabilized by UV irradiation and both MG132 and 
LMB treatment (Fig. 3 A). If a fluorescently labeled protein in 
any compartment in the imaged field spends some time in a 
compartment being bleached, its fluorescence will decay, and 
its transit across both compartments will thus be demonstrated 
(Lippincott-Schwartz et al., 2003). FLIP was performed by con-
stantly bleaching a cytoplasmic region of interest (ROI) com-
pletely surrounding the nucleus (see details in Fig. S2 A) and 
collecting images at fixed intervals. The relatively large area 
photobleached in these experiments caused significant photo-
bleaching inside nuclei. To account for this, PFA-fixed cells 
were imaged under the same conditions. As seen in Fig. 3 B,   
cytoplasmic  bleaching  rapidly  depletes  p53-EGFP  from  the 
nucleus  of  a  nonstressed  cell.  Estimated  nuclear  p53  clear-
ance half-life and decay profiles are shown in Fig. 3 (C and D), 
accumulation, termed here stress-sensitive export (SSE), and 
one that appears to be constitutively active, termed here stress-
independent export (SIE). This latter SIE leads to a proportion 
of p53 being exported even from a stressed nucleus, and this 
p53 can still be degraded if a nonstressed nucleus is present, 
as demonstrated by the heterokaryons of Fig. 1 (D and E) and 
Table I. In addition, the persistence of p53 after UV irradiation 
in the CHX-treated 6-h heterokaryons (Fig. 1, D and E) implies 
that commitment to SSE is extremely stable.
Nevertheless, the presence of a fraction of p53 that is still 
exportable after stress could be caused either by a persistent 
capacity to export p53 in irradiated nuclei (as proposed in the 
dual-export model) or by restoration of this capacity of the stressed 
nucleus by the presence of the fused normal nucleus. To dis-
criminate between these possibilities, we used FLIP of (nonfused) 
U2Os cells stably expressing p53-EGFP (U2Os–p53-EGFP), 
Figure 3.  FLIP analysis of p53 export. (A) Expression levels of p53-EGFP and endogenous p53 in U2Os–p53-EGFP cells compared with the parental cell 
line detected either with anti-p53 or anti-GFP antibodies (indicated). Cells were either untreated, UV irradiated (20 J/m
2), or treated with 10 µM MG132 
or 20 nM LMB for 6 h before lysis. Arrows indicate p53 bands. (B) FLIP by cytoplasmic photobleaching. U2Os–p53-EGFP cells were untreated, treated 
with UV (20 J/m
2), 20 nM LMB, or 10 µM MG132 for 2–4 h, or fixed with PFA. Images show a selection of frames for one cell for each condition. Nuclei 
were surrounded by ROIs of similar dimensions (yellow lines; see legend and DIC images in Fig. S2 A), which were repeatedly photobleached at full power 
with a 488-nm Ar laser. (C) Fluorescence decay half-lives (t1/2) for each one of the nuclei analyzed in each treatment. Half-lives were obtained by fitting a 
single exponential decay to each photobleaching time course (the median correlation for all the fittings was r
2 = 0.9972). P-values for the t tests for relevant 
comparisons between treatments are indicated. (D) Plots of time variation of nuclear fluorescence. Mean intensities were normalized to each initial intensity 
(t = 0). Plots show means (closed circles) ± SD of all nuclei analyzed for each treatment (numbers in C). Ctrl, control.JCB • VOLUME 194 • NUMBER 5 • 2011   694
micronuclei, leaving only one active mode of export (SIE), 
which is independent of nucleoli and, thus, is common to 
both types of micronuclei.
Interestingly, p53 stabilization by micronucleation has 
been observed before (for example, Granetto et al., 1996; Sablina   
et al., 1998), but although it was clear in these cases that DNA   
damage could not be the cause, to date, the mechanism of this 
stabilization has not been explained. Notably, the fact that not 
all micronuclei inside a cell show elevated p53 levels (Fig. 4 A;   
Granetto et al., 1996) makes p53 stabilization by micronucleation 
particularly difficult to explain by other stress signal transduc-
tion models, a phenomenon clearly explained by the nucleolar 
model of p53 regulation presented here. During a 48-h colce-
mid incubation, all micronuclei within a single cell will have 
shared a common proteome and transcriptome. This is observed 
when labeling for MDM2 and p21, transactivation targets of 
p53 (Ljungman, 2000), in which both proteins are equally dis-
tributed across both types of micronuclei (Fig. 4, C–E, plots). 
Importantly, although p53 levels in micronuclei strictly anti-
correlate with the presence of nucleoli (Fig. 4, A and E), MDM2 
levels are independent of it (Fig. 4, C and E), implying that 
p53 steady-state levels are not determined simply by the overall 
nuclear MDM2 levels as others have also observed (O’Hagan 
and Ljungman, 2004).
Nucleolar transit of p53
These results further support our proposal that the nucleolus is 
a critical regulator of p53 stability. Yet, the steady-state con-
centration of p53 in nucleoli is markedly lower than in the nu-
cleoplasm. These two observations can only be reconciled if 
nucleoplasmic p53 rapidly transits through the nucleolus (see 
Olson and Dundr [2005] for a discussion on nucleolar protein 
abundance  and  residence  times).  This  prediction  was  tested   
using FLIP on U2Os–p53-EGFP cells to determine whether 
p53-EGFP moves across nucleoli. Bleaching a nucleoplasmic 
ROI causes a progressive loss of p53-EGFP fluorescence across 
the nucleus, including nucleoli (Fig. 5 A and Fig. S2 B, position 
of the bleached ROIs). Placing the bleaching ROI inside a nucle-
olus eliminates all nucleoplasmic fluorescence at rates similar 
to nucleoplasmic bleaching (Fig. 5, A–C, comparison of decay 
half-life and decay profiles). When the bleaching ROI is placed 
within a nucleolus, some p53-EGFP photobleaching must occur 
in nucleoplasmic regions above and below the focused plane. 
However, in adherent U2Os cells, nucleoli span nearly all of the 
vertical cross section of the nucleus, leaving a minimal amount of 
nucleoplasm traversed by the photobleaching beam (Fig. S2 C).   
Thus, photobleaching occurring in this small, defocused nucleo-
plasmic region cannot account for a decay rate that is similar to 
nucleoplasmic photobleaching. Therefore, the majority of p53-
EGFP photodestroyed by placing an ROI over a nucleolus must 
be nucleolar. Thus, these results demonstrate that nucleoplasmic 
p53 is in constant transit through nucleoli and that essentially 
all of the nucleoplasmic p53 passes through the nucleoli during 
the time period analyzed. Furthermore, because the steady-state 
level of nucleolar p53 is lower than the nucleoplasmic, the com-
parable photobleaching rates indicate that nucleolar transit of 
p53 is faster than nucleoplasmic transit.
respectively (compare PFA-fixed cells). Both UV irradiation 
and LMB treatment reduce the rate of p53-EGFP fluorescence   
decay (significantly higher clearance half-life), yet p53 must 
still be exiting the nucleus because this decay is faster than 
that in fixed cells. Hence, loss of p53-EGFP fluorescence by 
cytoplasmic photobleaching confirms that some nuclear p53 is 
always exported, even after stress. Also, p53-EGFP is exported 
equally effectively after MG132 treatment, which agrees with 
data in Fig. 2 A. We also note that transiently expressed p53-
EGFP in p53-null cells (Saos-2) is exported at a similar rate 
to that of U2Os–p53-EGFP cells, indicating that unconjugated 
p53 is not required for this export (Fig. S4, A–C).
The processes contributing to the net p53-EGFP fluores-
cence intensities measured are export and possibly nuclear deg-
radation, the latter having only a minor contribution because 
the fluorescence decay half-lives are 10-fold shorter than our 
measured p53 decay rates. De novo synthesis and import do not 
contribute in these conditions because the bleaching ROIs com-
pletely surround the nuclei. Unfortunately, the FLIP method 
cannot  be  quantitated  with  sufficient  accuracy  to  determine 
whether, in stressed conditions, all p53 is exported more slowly 
or only a fraction is, but results from Fig. 1 (D and E) and   
Fig. 2 A (6-h heterokaryons) support the latter conclusion be-
cause only part of the p53 is lost from the stressed nucleus. It 
is noteworthy that, as Fig. 3 shows, even in LMB-treated cells, 
some p53 is still exported, suggesting that the p53-stabilizing 
effect of LMB may not be fully explained by inhibition of its 
nuclear export (see Discussion).
Micronucleation shows that the nucleolus 
drives p53 degradation
Our data suggest that although p53 stability is determined 
by posttranslational modifications, a key step in this chain 
of events must be stably associated with a nuclear structure. 
On the basis of our previous experiments, we here suggest 
that this structure is the nucleolus, which we also propose to 
control SSE. Accordingly, a nucleus without nucleoli should 
only  be  able  to  perform  SIE  and  would  therefore  show   
elevated p53 levels, providing that the relative contributions 
of SIE and SSE are comparable. Fig. 2 A suggests that this 
is the case. To test this prediction, we micronucleated cells 
stably expressing EGFP-tagged ribosomal protein L11 (U2Os–
L11-EGFP; Fig. S3 A) by exposing them to colcemid for   
48 h. Segregation of nucleolar-organizing regions in these cells 
produces nucleolated and nonnucleolated micronuclei (Fig. 4;   
Hernandez-Verdun et al., 1991) without detectable DNA dam-
age (Fig. S3, B and C, shows no detectable -H2AX signal 
[Bonner et al., 2008] and restoration of cycling by removal 
of colcemid, respectively; Granetto et al., 1996). In agree-
ment with the predicted effect of the presence of nucleoli, 
nonnucleolated  micronuclei  show  significantly  higher  p53 
levels than nucleolated ones (Fig. 4, A and E, plots), with the 
latter being similar to those of whole nuclei (not depicted). 
UV-irradiated cells, on the other hand, show a homogeneous 
distribution  of  p53  across  all  micronuclei,  irrespective  of 
the presence of nucleoli (Fig. 4, B and E, plots). This agrees 
with the abrogation of SSE by UV irradiation in nucleolated 695 Nucleolar regulation of p53 • Boyd et al.
Figure  4.  The  presence  of  nucleoli  determines 
p53  levels  in  micronuclei.  (A–D)  Examples  of 
U2Os–L11-EGFP cells micronucleated by incuba-
tion with 0.1 µg/ml colcemid for 48 h either un-
treated (A, C, and D) or UV irradiated 5 h before 
fixation (B) followed by staining for p53 (A and B,   
red), MDM2 p53 (C, red), or p21 p53 (D, red) 
and DAPI (blue). (E) Relative expression intensities 
in a series of cells treated and imaged as in A–D. 
The normalization parameter for each micronucle-
ated cell was the average of the mean intensity for   
the stained protein among all nucleolated (Yes)   
micronuclei.  Untreated  and  UV-irradiated  cells 
were analyzed separately. Plotted values are   
ratios, and therefore, no direct comparison can be 
made between the values for the untreated com-
pared with the UV-irradiated cells. Means (closed 
circles) ± SD are indicated. P-values correspond to 
t tests for expression differences (null hypothesis: 
mean protein staining levels are equal between 
nucleolated and nonnucleolated micronuclei).JCB • VOLUME 194 • NUMBER 5 • 2011   696
Figure 5.  Nucleolar transit of p53. (A) FLIP by nucleolar/nucleoplasmic photobleaching. Galleries show a selection of images from FLIP analysis per-
formed as in Fig. 3 with bleaching ROIs (yellow circles; see legend and DIC images in Fig. S2 B) located either in the nucleoplasm (Npl) or a nucleolus 
(Nol). UV irradiation and MG132 treatments were as in Fig. 3. (B) Plots of fluorescence decay half-life (fitting to single exponential plus constant; the 
median correlation for all the fittings was r
2 = 0.9982) for each nucleus analyzed in each treatment. Means (closed circles) ± SD are indicated. (C) Plots 
of time variation of nuclear fluorescence. Mean intensities were normalized to each initial intensity (t = 0). Plots show means ± SD of all nuclei analyzed 
(numbers in B).697 Nucleolar regulation of p53 • Boyd et al.
is both degraded more slowly and incapable of trafficking 
through nucleoli. Note that this reduced rate of clearance of   
p53-EGFP by nucleolar photobleaching confirms that nucleoplas-
mic photobleaching occurring above and below a targeted nucle-
olus cannot be responsible for the high FLIP decay rates observed 
in nucleolar photobleaching of untreated U2Os–p53-EGFP cells.
Nucleolar ubiquitylated p53 (Ub-p53)
Our data show that p53 stability is directly regulated by the nucleo-
lus. Ultimately, p53 degradation is a consequence of proteasome- 
mediated proteolysis of poly–Ub-p53, a process catalyzed by 
MDM2. Because MDM2 levels do not correlate with p53 levels 
in micronucleated nuclei, the role of nucleoli in regulating this 
process is likely to be either to promote p53–MDM2 interaction 
and/or to regulate the activity of p53 ubiquitylation by MDM2. 
However, to our knowledge, the presence of Ub-p53 in nucleoli 
has not previously been demonstrated. We therefore decided to 
fractionate cells into whole-cell, cytoplasmic, nucleoplasmic, and 
nucleolar fractions according to the protocol of Lam and Lamond 
(2006). Fig. 6 A (left column) shows the p53 content of all fractions 
in untreated U2Os cells (Fig. 6 B, fraction markers). Notably, p53 
As with nuclear export (Fig. S4, A and B), we also tested 
p53-EGFP transiently transfected into p53-null Saos-2 cells. In 
this case, p53-EGFP is cleared very slowly by nucleolar photo-
bleaching (in fact it is possible that it is not cleared at all, and we 
only see the effect of photobleaching the nucleoplasm above and 
below the targeted nucleoli; Fig. S4, D–F). We cotransfected 
wild-type p53 (at a plasmid ratio determined by Western blot-
ting to give a p53/p53-EGFP protein ratio similar to that ob-
served in stable U2OS–p53-EGFP; Fig. S4 G), and in these 
conditions, the clearance of nuclear p53 by nucleolar photo-
bleaching was restored. We confirmed by Western blot analysis 
of MDM2 and p21 expression that p53-EGFP was transcription-
ally active in Saos-2 cells, and because it induces massive cell 
death in transfected cells, we conclude that it is functional. How-
ever, as we show in Fig. S4 H, p53-EGFP has a longer half-life 
than wild-type p53, and this seems to be the main biochemical 
difference between the two species. This difference is entirely 
expected because EGFP-tagged proteins undergo reduced poly-
ubiquitylation and proteasomal degradation (Baens et al., 2006). 
Therefore, these results show that p53-EGFP, which is transcrip-
tionally competent but expected to be poorly polyubiquitylated, 
Figure 6.  Subcellular fractionation of U2Os cells. (A) Western blot of fractions of U2Os cells treated as indicated at the top developed with anti-p53.   
(top) Camera image. (middle) Scaled camera image. (bottom) Film long exposure. (B) Fraction markers B23, -tubulin (-tub), and histone H1 are as 
indicated. (C) Western blot as in A developed with anti-MDM2. (top) Camera image. (bottom) Film image. (A–C) Black boxes are used to indicate that the 
data are derived from two separate membranes. (D) Immunoprecipitation (IP) of MG132-treated U2Os cells. Cell lysates were immunoprecipitated with 
either anti-p53 or purified murine IgG and probed on a Western blot (WB) with either anti-p53 or anti-MDM2. Black boxes are used to indicate that pieces 
of a single membrane were probed in parallel with the indicated antibodies. (E) Ubiquitylated p53. U2Os cells were untreated or transfected with 6×His-
tagged ubiquitin (Ub) as indicated. Subcellular fractions were absorbed with Ni-NTA resin, and eluates were analyzed by Western blotting and detected 
with anti-p53. Black boxes are used to indicate that the lane for the nucleolar fraction (rightmost) was taken from a shorter exposure. Cy, cytoplasmic;   
Np, nucleoplasmic; No, nucleolar; Wh, whole fraction; WCE, whole-cell extract.JCB • VOLUME 194 • NUMBER 5 • 2011   698
(Fig. 6 A, center column). Fig. 6 E confirms the presence of   
Ub-p53 in all fractions by Ni-NTA pull-down of transfected His-
tagged ubiquitin. Nucleoplasmic and cytoplasmic fractions show 
a largely similar Ub-p53 pattern, and this is the pattern repre-
sented in the whole fraction (note that the nucleolar fraction is 
16 times concentrated by volume). Importantly, in the nucleo-
lar fraction, the first Ub-p53 band has a lower abundance relative 
to higher molecular masses, in comparison with the nucleoplas-
mic and cytoplasmic fractions in which this pattern is inverted   
(Fig. 6 A, middle of MG132 column; and see profiles in Fig. S5). 
This indicates that p53 is relatively more abundant in the nu-
cleoplasm and cytoplasm, whereas in nucleoli, more extensively 
ubiquitylated forms are relatively more abundant.
To study the effect of nuclear export inhibition on nucleolar 
Ub-p53, U2Os cells were treated with LMB and fractionated in 
parallel with untreated and MG132-treated cells. LMB stabilizes 
p53 to similarly high levels as MG132 (Fig. 6 A, top). However, 
there is a noticeable reduction in p53 ubiquitylation, particularly 
in the nucleolar fraction in which there are hardly any high mo-
lecular mass forms (Fig. 6 A, middle and bottom). This surprising 
result suggests that an effect of LMB may be to prevent p53 from 
being ubiquitylated rather than preventing Ub-p53 from reaching 
proteasomes. We therefore analyzed the subcellular distribution 
of MDM2 under the same three conditions. As expected, MDM2 
is abundant in nucleoli, in which it is detectable even without sta-
bilization. In addition, and as expected, total MDM2 in intact 
cells is stabilized by both MG132 and LMB (Fig. 6 C). However, 
these inhibitors introduce two important changes: the 90-kD band 
is highly enriched in nucleoli after MG132 treatment, and   
although LMB increases total MDM2 levels, this increase is not 
paralleled in nucleoli in which it becomes less abundant. Hence, 
the increase in Ub-p53 induced by MG132 follows the observed 
increase in 90-kD MDM2 in nucleoli, whereas the p53 stabiliza-
tion with relatively low ubiquitylation induced by LMB accompa-
nies the relatively lower abundance of 90-kD MDM2 in nucleoli. 
The 90-kD isoform is the main p53-interacting isoform of MDM2 
as shown by immunoprecipitation (Fig. 6 D), suggesting that nu-
cleolar 90-kD MDM2 is critical for overall p53 ubiquitylation.
To confirm the presence of Ub-p53 in all the fractions, we 
applied pull-down of transiently transfected 6×His-tagged ubiq-
uitin. Western blotting with anti-p53 (Fig. 6 E) reveals the ex-
pected high molecular mass bands. Next, we immunoprecipitated 
p53 from all fractions and probed the precipitates for polyubiqui-
tylated forms (antibody FK1) or for both mono- and polyubiqui-
tylated forms (antibody FK2). There are two striking features of 
this experiment. First, in Fig. 7 C, it is clear that polyubiquitylated 
forms of p53 are enriched in the nucleolar fraction. Second, as   
Fig. 7 (A and B) shows, proteasome-sensitive forms of p53 are 
greatly enriched in the nucleolus. Thus, our results provide evidence 
of nucleolar compartmentalization of p53 polyubiquitylation.
Discussion
Our previous study (Rubbi and Milner, 2003) demonstrated a 
critical role for the nucleolus in regulating p53 in response to 
stress. The aim of the present work was to determine whether 
regulation of p53 stability by nucleolar stress is likely exerted 
appears to be most abundant in the cytoplasm, which may reflect   
both  the  size  of  the  cytoplasmic  compartment  and/or  some 
leakage from nuclei during fractionation. Longer film exposure   
(Fig. 6 A, bottom) shows high molecular mass p53 bands consis-
tent with ubiquitylation. To visualize Ub-p53, proteasomal deg-
radation was inhibited with MG132 (Fig. 6 A, center column). As 
expected, p53 was stabilized, and more slowly migrating (likely 
ubiquitylated) forms were detectable in all fractions, including 
nucleoli. The nucleolar fraction in Fig. 6 A has a distinctive band-
ing pattern, which ensures that the presence of Ub-p53 in nucleoli 
is genuine and not caused by contamination from other fractions 
Figure  7.  Ubiquitylation  of  p53  immunoprecipitated  from  subcellular 
fractions. (A–D) Western blots of immunoprecipitated (IP) p53. (E) Western 
blot of whole-cell lysate. U2Os cells were grown untreated or treated with 
10 µM MG132, fractionated as in Fig. 6, and immunoprecipitated with 
anti-p53 (DO-1). Antibody FK2 (A and B) detects mono- and polyubiqui-
tylated proteins; FK1 (C) detects only polyubiquitylated proteins; ab2433 
(D) is a rabbit antibody that detects p53, which avoids the signal from the 
murine antibody;and DO-1 (E) detects p53. Molecular masses (MM) are 
given in kilodaltons. Cyt, cytoplasm; Npl, nucleoplasm; Nol, nucleolus;   
IB, immunoblot; Ub, ubiquitin.699 Nucleolar regulation of p53 • Boyd et al.
implying the existence of SSE and SIE pathways. If SSE de-
pends  on  nucleolar  function,  nuclei  without  nucleoli  would 
only perform SIE and show higher p53 levels. Micronucleation 
experiments confirmed this prediction (Fig. 4), demonstrating 
that nonnucleolated micronuclei express higher levels of p53, 
whereas levels across micronuclei become homogeneous after   
UV irradiation (SSE block). Interestingly, direct nucleolar con-
trol of p53 stabilization appears to be the only way to explain 
the  paradoxical  behavior  of  p53  in  micronucleated  cells,  in 
which not only is it stabilized in the absence of any obvious 
DNA damage, but this stabilization occurs only in some, but not 
all, of the micronuclei within a cell (Granetto et al., 1996). The 
dual export and nucleolar regulation of p53 are summarized in 
the diagram presented in Fig. 8.
Further evidence that the nucleolus is an integral part of 
the p53 regulation machinery comes from FLIP data revealing 
that essentially all nuclear p53 transits through nucleoli (Fig. 5) 
and from subcellular fractionation experiments that show that 
nucleolar p53 is enriched in ubiquitylated forms (Fig. 6 and Fig. 7),   
and particularly, in polyubiquitylated, proteasome-sensitive ones 
(Fig. 7). This association between p53 polyubiquitylation and 
nucleoli is further supported by first the poor (or null) nucleo-
lar transit of p53-EGFP only (Fig. S4 D) and second the cor-
relation between high p53 ubiquitylation and enrichment in the 
predominant p53-interacting form of MDM2 (90 kD) in the nu-
cleolus observed under MG132 treatment (Fig. 6 C). Although 
the possibility of newly polyubiquinitylated p53 being rapidly 
through diffusible (signaling) or stable (structural) components 
of nucleoli. To study the nature of the signals regulating p53 
stability, heterokaryon assays were performed in which nuclei 
from cells with different p53 stability and steady-state levels 
coexisted within a common cytoplasm. The simplicity of the 
heterokaryon assay demonstrates unequivocally that the steady-
state level of p53 in a nucleus, be it the normal or the DNA 
damage-induced level, is not affected by the status of p53 regu-
lation in another nucleus (Fig. 1). For each nucleus studied, the 
proteome generated by another (cocytoplasmic) nucleus (with 
or without a different stress history) during a 6-h postfusion 
could not alter its p53 level, regardless of the origin (human 
or murine) of the p53 being monitored. To our knowledge, 
the question of whether p53 stability can be signaled from one 
nucleus to another had never been addressed before. This ques-
tion is crucial because it imposes a constraint on models for 
p53 stabilization. In our system, we find that the p53 steady-
state level is a property intrinsic and local to each nucleus.   
Mobile intermediates relaying nucleolar stress into inhibition of 
MDM2-mediated p53 ubiquitylation, which appear to be free 
to move between nucleus and cytoplasm (see Fig. S1), cannot 
satisfactorily explain the localized p53 stabilization observed in 
our heterokaryon assays.
From these findings, we went on to determine whether the 
nucleolus fulfils other requirements for p53 regulation, namely 
association with export and ubiquitylation. We have found that 
UV only partially abolishes export and degradation (Fig. 1),   
Figure 8.  p53 nucleolar control and dual-export model. Results suggest that MDM2 promotes monoubiquitylation of p53 in the nucleoplasm and that 
mono–Ub-p53 is exported via the SIE pathway (a possible consequence of this export may be p53 movement to mitochondria). When MDM2 localizes 
in nucleoli, p53 is polyubiquitylated, and this modification promotes export (SSE) and proteasomal degradation of p53. The proposed points of action of 
factors that lead to p53 stabilization are indicated. p53 may also be degraded by nuclear proteasomes.JCB • VOLUME 194 • NUMBER 5 • 2011   700
The  mechanism  of  p53  stabilization  by  inhibition  of 
CRM1 may also need to be reconsidered. LMB treatment stabi-
lizes p53 to the same extent that MG132 does but does so with a 
significantly lower level of ubiquitylation than the latter (Fig. 6), 
which suggests that under LMB treatment, MDM2 fails to reach 
p53 (and nucleoli) efficiently (Fig. 8). A possible precedent for 
an  effect  of  CRM1  inhibition  on  intranuclear  movement  of 
MDM2 may be the accumulation of MDM2 in nuclear bodies 
induced by LMB (as well as p53 stabilization) reported by Laín 
et al. (1999). This effect of LMB on MDM2 is not unexpected 
in view of the recent work indicating that CRM1 has a role 
in intranuclear transport of nucleolar and preribosomal com-
ponents (Sleeman et al., 2001; Boulon et al., 2004; Sleeman, 
2007; Muro et al., 2008). Interestingly, it has been reported that 
human papilloma virus E6 expression reduces (Freedman and 
Levine, 1998) and even abolishes (Gray et al., 2007) p53 stabi-
lization by LMB. This indicates that CRM1 inhibition by LMB 
prevents MDM2-dependent p53 degradation but is ineffective 
to prevent p53 degradation when p53 is polyubiquitylated by 
other ligases. Taking these data together, it seems reasonable 
to hypothesize that LMB stabilizes p53 through inhibition of 
nuclear transit of MDM2, rather than through nuclear reten-
tion of p53 (Fig. 8). In view of the interactions of MDM2 with 
ribosomal proteins (Colombo et al., 2002; Lohrum et al., 2003; 
Zhang et al., 2003; Bhat et al., 2004; Dai and Lu, 2004; Dai 
et al., 2004; Jin et al., 2004) and ribosomal protein–ribosomal 
RNA complexes (Marechal et al., 1994) as well as nucleolar 
transit (Tao and Levine, 1999b), it is likely that intranuclear 
transport of MDM2 occurs in association with ribosomal bio-
genesis. Thus, the interpretation of data in which p53 levels are 
modulated  by  up/down-regulation  of  ribosomal  components 
(hence, of ribosomal biogenesis) should take into account pos-
sible effects on MDM2 intranuclear transport and on its capac-
ity to reach nucleoli.
The correlation between p53 export and degradation pre-
sented here and elsewhere appears to indicate that in normal 
growth conditions, p53 is degraded in the cytoplasm. However, 
it should be stressed that the evidence currently available for the 
subcellular compartment of proteasomal degradation of p53 is 
indirect and may well be confounded by the rapid nucleocyto-
plasmic exchange of p53. The present work highlights the prob-
lems with attempts to identify such compartments by either 
proteasome or nuclear export inhibition while looking only at 
p53 stabilization. Nuclear accumulation of p53 after MG132 
treatment does not necessarily imply that p53 is degraded by 
nuclear proteasomes (Li et al., 2003); as shown here (Fig. 2 A), 
p53 continues to move between the nucleus and the cytoplasm 
after proteasome inhibition, and the observed nuclear accumu-
lation of p53 appears simply to reflect nuclear import/export 
rates (Fig. 8). However, the correlation between nuclear export 
inhibition by LMB and p53 stabilization does not prove cyto-
plasmic degradation either because, as mentioned in the previ-
ous paragraph, CRM1 appears to participate in intranuclear 
transport, especially in association with ribosomal biogenesis. 
Thus, the question of cytoplasmic versus nuclear degradation of 
p53 in normal growth conditions is still open, and the answer 
may well be both.
recruited to nucleoli cannot be discarded, our data, especially 
the undetectable levels of poly–Ub-p53 in the nucleoplasmic 
fraction (Fig. 7), support the conclusion that p53 polyubiqui-
tylation must occur in nucleoli (interestingly, Xirodimas et al. 
[2001] reported a need for an intact MDM2 nucleolar localiza-
tion signal for p53 polyubiquitylation). Importantly, recent data 
suggesting that the nucleolus may be a site of ubiquitylation 
(Welcker et al., 2004; Mekhail et al., 2005; Stavreva et al., 2006; 
Latonen et al., 2011) strongly support this notion.
The  existence  of  an  export  pathway  that  can  operate   
under stress (SIE) can explain how cytoplasmic functions of 
p53  could  be  performed  during  a  stress  response  in  which   
nucleolus-dependent export (SSE) is impaired. The two-pathway 
model agrees with recent evidence suggesting that p53 mono- 
and polyubiquitylation constitute distinct events, possibly with 
different biological consequences. Monoubiquitylation appears 
to promote p53 nuclear export not leading to degradation, the 
latter requiring polyubiquitylation (Geyer et al., 2000; Li et al., 
2003; Brooks and Gu, 2006; Carter et al., 2007), and more recently, 
p53 monoubiquitylation has been strongly linked to mitochon-
drial  translocation  and  transactivation-independent  apoptosis 
(Marchenko and Moll, 2007). Thus, it seems reasonable to hy-
pothesize that poly–Ub-p53 follows a nucleolar route of export 
(SSE) destined for degradation, whereas mono–Ub-p53 is directly 
exported to the cytoplasm (SIE). Other p53 modifications, such 
as SUMOylation and NEDDylation, contribute to p53 export 
(Carter et al., 2007; Xirodimas, 2008), and clearly, the contribu-
tions of these to the present model will require investigation.
Recent findings in ribosome biogenesis are also consistent 
with the notion of nucleolar p53 regulation. Although nucleolar 
ubiquitylation of p53 may be a new concept, it has already been 
observed for c-Myc and the von Hippel-Landau tumor suppres-
sor (Welcker et al., 2004; Mekhail et al., 2005). Importantly, 
ubiquitylated proteins accumulate in nucleoli (Stavreva et al., 
2006), and it is likely that excess ribosomal proteins are cleared 
by ubiquitylation and nuclear proteasomal degradation (Lam   
et al., 2007). With respect to transport, Sherr and Weber (2000) 
have proposed that p53 and MDM2 may follow other proteins 
in exploiting the active export of ribosomal subunits by “riding 
the ribosome.” Interactions between p53 and ribosomal L pro-
teins and ribosomal RNA (Fontoura et al., 1992, 1997; Marechal 
et al., 1994) provide a possible molecular basis for this transit. 
Therefore, the nucleolar role in transport of both p53 and   
MDM2 must be considered when interpreting changes in protein– 
protein interactions after ribosomal stress. The increased detec-
tion of proteins binding either p53 or MDM2 after nucleolar 
stress  (Colombo  et  al.,  2002;  Lohrum  et  al.,  2003;  Zhang   
et al., 2003; Bhat et al., 2004; Dai and Lu, 2004; Dai et al., 
2004; Jin et al., 2004) is usually interpreted to reflect increased 
association rates enabled by relocalization of nucleolar proteins 
to the nucleoplasm (hence, signaling for cell stress). However, 
because recurring protein associations and dissociations accom-
pany  ribosome  biosynthesis  and  export  (Olson  and  Dundr, 
2005; Hernandez-Verdun, 2006; Emmott and Hiscox, 2009),   
it should be noted that this increased binding may also reflect   
reduced dissociation rates caused by inhibition of transport by 
ribosomal stress.701 Nucleolar regulation of p53 • Boyd et al.
Cells were blocked in PBS-T + 10% normal donkey serum (PBS-TS) for   
20 min. Primary and secondary antibodies were incubated in PBS-TS for   
1 h with four washes in PBS-T. The primary antibodies used in this study 
were DO-1 (specific for human p53; EMD), PAb246 (specific for murine 
p53; EMD), anti-B23 mAb (EMD), goat polyclonal (Santa Cruz Biotechnol-
ogy, Inc.), and antiphosphorylated histone H2AX (-H2AX; BioLegend). 
Secondary antibodies were raised in donkey, each one cross-absorbed for 
the species of the other primaries in the assay and labeled with either FITC 
or Cy3 (Jackson ImmunoResearch Laboratories, Inc.). FITC-phalloidin was 
added at 50 µg/ml together with the secondary antibody to visualize which 
nuclei were inside a common cytoplasm. Coverglasses were mounted in 
Mowiol 4–88 with 10 mg/ml 1,4-diazabicyclo[2.2.2]octane. Imaging was 
performed with a 100× 1.4 NA oil immersion objective in a microscope 
(TE300; Nikon) equipped with a camera (Orca AG; Hamamatsu Photonics). 
Images were acquired using Simple PCI software (Hamamatsu Photonics) 
and imported into ImageJ (National Institutes of Health) using the LOCI Bio-
Formats Java library for ImageJ. Images were preprocessed by subtracting a 
dark current reference image and normalizing with an illumination reference 
obtained by averaging 10 images of a uniform layer of fluorescein in mount-
ing medium. All processing and analysis was performed in ImageJ. Nuclear 
ROIs were either automatically or manually defined using masks from the 
corresponding DAPI images. Calculations used average p53 fluorescence 
intensity, hence reflecting p53 concentrations rather than total mass. How-
ever, integration over the total nuclear area did not alter the results. Statisti-
cal analyses were performed using SigmaPlot (Systat Software, Inc.). Because 
imaging exposure was optimized for each field, a paired t test was used, 
pairing the different categories of nuclei within each image. For flow cytom-
etry, trypsinized cells were fixed with cold 70% ethanol, washed with PBS-T, 
resuspended in 50 µg/ml propidium iodide and 1 U/ml RNase A (Sigma-
Aldrich), and after 1 h, analyzed in a flow cytometer (FACsort; BD).
FLIP
U2Os–p53-EGFP and transfected Saos-2 cells were cultured on 19-mm 
coverglasses  bound  to  35-mm  plastic  dishes  and  mounted  in  a  heat 
(37°C)-, humidity (saturated)-, and CO2 (5%)-controlled stage (Carl Zeiss) 
with DME + 25 mM Hepes before observation. UV irradiation, MG132, 
or LMB was applied as before. Cells were imaged in a confocal scan-
ning system (LSM 710; Carl Zeiss) using a 63× 1.4 NA oil immersion 
objective and Zen acquisition software (Carl Zeiss). Differential interfer-
ence contrast (DIC) images were acquired using the 633-nm laser line to 
avoid GFP photobleaching. Bleaching was performed using the 488-nm 
line of a 25-mW Ar ion laser at 100% power on cycles of either 50 
(nuclear photobleaching) or 70 repetitions (cytoplasmic photobleaching), 
each followed by imaging at 5% laser power. For cytoplasmic photo-
bleaching, ROIs were manually defined at a distance of 1 µm from 
the cell nucleus, leaving nuclei unbleached but completely surrounding 
them. ROIs were inscribed in 26.4 × 26.4–µm squares (200 × 200 pixels;   
694.7  µm
2),  thus  ensuring  identical  bleaching  times  for  all  images   
(2.2 s between image collections for a total of 70 frames). Because of cell 
movement during acquisition, only time points at which the nucleus was 
completely included and not touching the bleaching regions were used 
for analysis. For nucleolar and nucleoplasmic photobleaching, ROIs were 
0.75-µm
2 circles (11-pixel diameter, a size that ensured full nucleolar 
inclusion and tolerance of cell movement) bleached for 1.7 s between 
image collections (for a total of 70 frames). Because of cell movement, 
DIC images were collected before and after FLIP acquisition to ensure that 
the bleaching ROIs remained within the target region (nucleolus or nu-
cleoplasm) during imaging. Time series were imported into ImageJ using   
the LOCI Bio-Formats Java library. Bleaching correction (using reference, 
unbleached  cells)  and  calculations  (parameter  fitting  of  exponential   
decay curves) used average fluorescence intensities over manually de-
fined ROIs and were all performed in ImageJ.
FRAP
U2OS–L11-EGFP cells were placed in an incubation chamber in a confo-
cal microscope (LSM 710) as for FLIP and photobleached with the 488-nm 
line of a 25-mW Ar ion laser at full intensity for 0.5 s over an ROI covering   
either a whole nucleolus, a 1.685-µm
2 circular area within the nucleo-
plasm, or whole nuclei. Immediately after, images were collected at 3% 
laser power every 0.197 s (10 s for whole nuclear FRAP). Acquisition 
bleaching was compensated using whole nuclear fluorescence for nucleolar 
FRAP, a nucleoplasmic ROI for nucleoplasmic FRAP, or total fluorescence of 
a group of cells (whole nuclear FRAP). Nucleoli and nucleoplasm showed 
an extremely fast but partial recovery of fluorescence, with total recovery 
taking several minutes. For this reason, comparisons of recovery times and 
Although the concept of p53 regulation occurring in asso-
ciation with nucleoli may be innovative to p53 biology, it per-
fectly matches many known features of MDM2/p53 biochemistry. 
As mentioned in this section, MDM2 transits through nucleoli 
(Mekhail et al., 2005) and appears to be exported to the cyto-
plasm via the nucleolus (Tao and Levine, 1999b), and it is also 
possible that MDM2 may require its nucleolar localization sig-
nal to polyubiquitylate p53 but not to monoubiquitylate p53 or 
autoubiquitylate (Lohrum et al., 2000). In addition, despite hav-
ing its own nuclear export signal (NES), p53 nuclear export de-
pends on the ubiquitylation capacity of MDM2 (intact RING 
finger domain) but not on the MDM2 NES (Boyd et al., 2000; 
Geyer et al., 2000), implying that the p53 NES is not fully effec-
tive for exporting p53 unless MDM2 ubiquitylates it and that 
MDM2 does not chaperone p53 out of the nucleus. Hence,   
although p53 ubiquitylation is intimately linked to its export, the 
transit of MDM2 through the nucleolus appears to be necessary 
for p53 ubiquitylation and export. Thus, this work introduces the 
novel concept that these biochemical events are associated with 
and depend on functional nucleoli. It also demonstrates that the 
nucleolus is a site of stress-dependent regulation of a protein not 
directly related to ribosomal biogenesis. Importantly, the direct 
nucleolar role in p53 regulation implies that the whole nucleolar 
function, including ribosomal biogenesis, rather than diffusible 
components, might define new targets for therapeutic p53 acti-
vation that need not depend upon inducing DNA damage.
Materials and methods
Cells and culture conditions
Human osteosarcoma cells (U2Os) and derived clones, Saos-2 and clone 
9 cells (derived from p53-null H1299 cells stably overexpressing MDM2; 
Maguire  et  al.,  2008),  and  murine  3T3  fibroblasts  were  cultured  in   
DME + 10% FCS. For fixed-cell microscopy, cells were cultured in 13-mm-diam   
coverglasses and, for live imaging, in 42-mm coverglasses. U2Os–p53-EGFP   
and U2Os–L11-EGFP cells were generated by transfecting U2Os cells either 
with plasmid pp53-EGFP (Takara Bio Inc.) or L11-EGFP (Sundqvist et al., 2009;   
a gift from D. Xirodimas, Centre National de la Recherche Scientifique–
Centre de Recherche de Biochimie Macromoléculaire, Montpellier, France), 
respectively, using transfection reagent (GeneJuice; EMD) at a 1:3 (wt/vol) 
DNA/reagent ratio. Stable clones were selected with 0.5 mg/ml G418 
(EMD) and identified for cloning by fluorescence observation. Transient 
transfection in Saos-2 cells was performed similarly.
Heterokaryon and micronucleation assays
For cell fusion assays, seeded cells were grown for 24 h at a starting 
density of 4 × 10
4 cells per 13-mm coverglass (in 24-well plates). When 
applicable, UV irradiation was performed at 20 J/m
2 5 h before fusion. 
Overlaid cells were seeded 3–5 h before fusion at 4 × 10
4 cells per 13-mm 
coverglass. Fusion was performed by washing cells in PBS, adding 50% 
polyethyleneglycol 3000 (Sigma-Aldrich) at 37°C in PBS for 2 min with 
gentle rocking, and washing twice with HBSS without phenol red (Invitro-
gen). Cells were then cultured in DME + FCS with the appropriate inhibitors 
added for a further 6 h before fixation. Immunofluorescence (see next sec-
tion) included FITC-phalloidin (Sigma-Aldrich) to identify fused nuclei and 
DAPI to differentiate human and murine nuclei. Micronucleation was per-
formed on U2Os–L11-EGFP cells because these offered the best identifica-
tion of nucleolated and nonnucleolated micronuclei in both unstressed and 
UV irradiation conditions. Micronuclei were induced by adding 0.1 µg/ml 
colcemid (Sigma-Aldrich) to cultures and incubating for 48 h. UV irradiation 
was performed 6 h before fixation while still keeping colcemid present.
Immunofluorescence
Cells grown in coverglasses were washed twice in PBS and fixed for 10 min 
with 4% PFA (Sigma-Aldrich) followed by permeabilization for 2 min in 
0.5% Triton X-100 in PBS and a wash in PBS + 0.01% Tween 20 (PBS-T). JCB • VOLUME 194 • NUMBER 5 • 2011   702
fractionation for 10 min on ice and centrifuged for 10 min at 4°C at 13,000 
rpm. Volumes of lysate containing 4 mg total protein were supplemented to 
0.5 ml with SLIP + PI. Lysates were precleared for 1 h with 50 µl of washed 
protein G–Sepharose beads (Sigma-Aldrich), and then, 2 µg antibody was 
added, and lysates were incubated for 1 h. Protein G–Sepharose beads 
were then added and incubated for 2 h with mixing. Finally, beads were 
washed three times with SLIP + PI and resuspended in SDS-PAGE loading 
buffer. For immunoprecipitation from subcellular fractions, the same proce-
dure was used except that SLIP buffer was replaced by radioimmunoprecipi-
tation assay buffer (150 mM NaC1, 1% NP-40, 0.5% deoxycholate, 0.1% 
SDS, and 50 mM Tris, pH 8.0) + PI (Lam and Lamond, 2006). The aqueous 
fractions (cytoplasmic and nucleoplasmic) were supplemented with 1:10 vol 
of 10× radioimmunoprecipitation assay buffer + PI.
Online supplemental material
Fig. S1 shows the half-life of p53 in cells used in heterokaryons, extends het-
erokaryon analyses for local p53 stabilization and leakage into nonstressed 
nucleus, addresses locality of putative p53 destabilizing factors in hetero-
karyons (MDM2, B23 translocation, and p53 Ser15 phosphorylation), and 
the transport of a ribosomal protein (FRAP with L11-EGFP). Fig. S2 shows 
controls for FLIP analyses. Fig. S3 shows controls for micronucleation experi-
ments. Fig. S4 shows photobleaching behavior of transiently expressed p53-
EGFP in a p53-null background (Saos-2). Fig. S5 shows intensity profiles for 
p53 Western blots from Fig. 6 A. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.201105143/DC1.
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Subcellular fractionation
Cytoplasmic, nucleoplasmic, and nucleolar fractions of U2Os cells were 
prepared  following  Lam  and  Lamond  (2006),  using  cultures  from  five 
10 × 15–cm dishes for each treatment as required. In brief, cells were 
homogenized in hypotonic buffer (10 mM Hepes, 10 mM KCl, 1.5 mM 
MgCl2, and 0.5 mM dithiothreitol, pH 7.9) using a Potter homogenizer, 
and the cytoplasmic fraction was recovered by centrifugation (218 g for   
5 min). The nuclear pellet was resuspended in 0.25 M sucrose (plus 10 mM 
MgCl2) and cleared by centrifugation over a cushion of S2 solution (0.35 M   
sucrose and 0.5 mM MgCl2). Nuclei were resuspended in S2 solution and   
sonicated using a sonicator with a microtip (GEX600; Sonics & Materials, 
Ltd.) at 30% amplitude in 10-s intervals followed by phase-contrast moni-
toring for nuclear disruption. The sonicated sample was layered onto a 
cushion of 0.88 M sucrose and 0.5 mM MgCl2, and the nucleoplasmic   
upper  phase  and  nucleolar  pellet  were  recovered  after  centrifugation 
(3,000 g for 10 min). All steps were performed at 4°C. The different sub-
cellular fractions were collected into a similar final volume, except for the 
nucleolar fraction (volume 16.5× smaller), so p53 band intensities are 
proportional to total p53 mass in each fraction but not to concentration. All 
buffers contained EDTA-free protease inhibitor (PI) cocktail (Set III; EMD) 
plus 10 mM N-ethylmaleimide (Sigma-Aldrich) as a deubiquitinase inhibi-
tor (Brady et al., 2005). After fractionation, samples were added SDS to 
a final 1%, and the nucleolar pellet was dissolved in SDS-PAGE loading 
buffer with sonication if necessary. Samples from all three treatments corre-
sponding to a same subcellular fraction were adjusted to have the same total 
protein concentration. Total protein was quantitated using protein reagent 
(DC Protein Assay; Bio-Rad Laboratories). To capture His-tagged ubiquitin, 
cells in 5 × 15–cm dishes were transfected (GeneJuice) with a plasmid   
expressing 6×His-ubiquitin for 36 h and subjected to subcellular fractionation, 
except that the cytoplasmic and nucleoplasmic fractions were precipitated 
with 10% trichloroacetic acid, centrifuged, and washed with acetone. Pellets 
were then processed to purify the 6×His-ubiquitin complexes as described 
by Xirodimas et al. (2001). In brief, pellets were dissolved in 6 M gua-
nidinium-HCl, 0.1 M Na2HPO4, 0.01 M Tris/HCl, 5 mM imidazole, and   
10 mM -mercaptoethanol (BME), pH 8.0, and incubated with Ni-NTA beads 
(QIAGEN) for 4 h at RT. Beads were then sequentially washed for 5 min at 
RT with (a) 6 M guanidinium-HCl, 0.1 M Na2HPO4, 0.01 M Tris/HCl, and   
10 mM BME, pH 8.0; (b) 8 M urea, 0.1 M Na2HPO4, 0.01 M Tris/HCl, 
and 10 mM BME, pH 8.0; (c) 8 M urea, 0.1 M Na2HPO4, 0.01 M Tris/HCl, 
and 10 mM BME, pH 6.3; (d) buffer c plus 0.2% Triton X-100; (e) buffer c 
plus 0.1% Triton X-100; and (f) 200 mM imidazole, 0.15 M Tris/HCl, pH 
6.7, 30% glycerol, 0.72 M BME, and 5% SDS. Supernatants from step f 
were added SDS-PAGE loading buffer and analyzed by Western blotting.
Western blotting and immunoprecipitation
Cells were cultured in 60-mm Petri dishes, treated as required, trypsinized, 
and lysed in 1% SDS, 0.5% NP-40, 150 mM NaCl, 2 mM EDTA, and   
50 mM Tris, pH 7.4. For p53 half-life determinations, cells were incubated 
in 6-well plates with 50 µg/ml CHX for the required times and then lysed 
with 200 µl of SDS-PAGE loading buffer and sonicated at 4°C. Protein 
content was determined using the DC protein reagent and used to normal-
ize the loading amounts. After SDS-PAGE, Western blotting was performed 
by detection of p53 with DO-1 or rabbit polyclonal (ab2433; Abcam), 
MDM2 with IF-2 (EMD), B23 with goat polyclonal, histone H1 with mAb 
(Santa Cruz Biotechnology, Inc.), and -tubulin with mAb (Abcam). For 
the chemiluminescence reaction, a reagent was used (SuperSignal West 
Dura; Thermo Fisher Scientific), and images were collected using either an 
imaging workstation (IS4000MM; Kodak) or autoradiographed. Immuno-
precipitation was performed according to Brady et al. (2005). In brief, 
trypsinized cell pellets were lysed in standard lysis and immunoprecipitation 
(SLIP) buffer (50 mM Hepes, 150 mM NaCl, 10% glycerol, 0.1% Triton 
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